Ipamorelin: what it is studied alongside

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS), also referred to in the literature as a ghrelin mimetic and as a growth hormone-releasing peptide. It belongs to the same pharmacological class as GHRP-2, GHRP-6, and hexarelin, all of which are grouped among the peptides marketed as research compounds intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis [3]. The evidence block supplied for this page does not provide a sequence, molecular formula, or molecular weight for the compound, so none are stated here.

The work centres on the growth hormone secretagogue receptor 1a (GHSR-1a), the receptor family through which ghrelin mimetics such as ipamorelin are described as acting [9].

Research Studies

Ipamorelin and post-operative gastrointestinal function after bowel resection

A registered clinical trial examined post-operative administration of Ipamorelin in patients who had undergone partial small and/or large bowel resection. The stated expectation of that study was a reduction in time to recovery of gastrointestinal function in the treated patients [1]. This is a human clinical trial record; the evidence block reports the study's purpose and expectation rather than a completed result.

Ipamorelin and post-operative ileus

A separate registered trial was designed to determine whether ipamorelin is safe and effective in the management of post-operative ileus [2]. As with the resection study above, the evidence block supplies the trial's objective, not an outcome.

Ipamorelin and cisplatin-induced weight loss in ferrets

In a ferret model, the GHSR-1a agonists anamorelin and ipamorelin were investigated for their ability to alleviate weight loss and the inhibition of feeding observed during the acute and delayed phases of cisplatin-induced emesis. The same study examined the potential of anamorelin to inhibit electrically field stimulation-induced contractions of isolated tissue [9]. This is animal and isolated-tissue work; it is not human data.

Ipamorelin acetate and the hypothalamic-pituitary-testicular axis in a cichlid fish

In the tilapia Oreochromis mossambicus, ipamorelin acetate was administered to examine its impact on the reproductive axis, building on the prediction that ghrelin, a peptide found in brain and gut, plays a role in the control of several physiological systems in fish [10]. This is a non-mammalian animal model and does not translate directly to human physiology.

Ipamorelin and other GH-IGF-1 axis peptides in self-administration protocols

A review of performance-enhancing peptides described the agents most commonly encountered in clinical practice and in online self-administration protocols. That list includes GHRH analogues such as sermorelin, tesamorelin, and CJC-1295 with and without DAC; growth hormone secretagogues including GHRP-2, GHRP-6, hexarelin, and ipamorelin; the GH fragment AOD9604 (hGH 176-191); and an IGF-1 analogue [3]. Ipamorelin therefore appears in the literature as one member of a broader class rather than as a standalone subject.

Ipamorelin and the purity of research-grade peptides sold direct to consumers

An evaluation of research-grade peptides marketed directly to consumers measured purity, measured abundance, and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives. The dataset covered 6,441 products [4]. The study's framing is that peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market selling preparations directly to consumers for self-administration, including for purported musculoskeletal recovery, muscle hypertrophy, fat loss, and athletic performance [4]. This work concerns the supply chain and product quality of the category, not the pharmacology of ipamorelin specifically.

Ipamorelin within reviews of peptide therapeutics in aging

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. Searches covered PubMed, Scopus, and regulatory databases from inception through January 2026 [5]. Ipamorelin sits within the class of GH-IGF-1 axis peptides such reviews survey.

Ipamorelin and reviews of peptides in sports medicine

Reviews of peptide therapies for musculoskeletal injuries and athletic performance describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and note that use in sports medicine is expanding on patient demand for accelerated injury recovery and performance enhancement. These reviews contrast peptides that have undergone a rigorous approval process evaluating safety and efficacy with a parallel gray market of unapproved compounds operating largely outside regulatory oversight [6][7]. A related review of peptide supplements in sports medicine notes that the market has grown on marketing claims of enhanced performance and accelerated recovery, and that these products are often perceived as low risk despite the absence of efficacy or safety data [11]. A structured narrative review of injectable peptides in sports medicine makes a comparable point: clinical adoption has outpaced high-quality evidence and regulatory consensus, and the review set out to summarise human and translational evidence published from January 1, 2020 onward [12].

Ipamorelin and the gap between clinical evidence and self-administration

The review of performance-enhancing peptides modulating the GH-IGF-1 axis is explicitly framed around bridging the gap between clinical evidence and patient self-administration [3]. That framing is the recurring theme across the category literature: registered trials exist for defined clinical indications such as post-operative GI recovery [1][2], while the consumer-facing use of the same class occurs largely outside those indications [3][4][6][7].

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function — https://clinicaltrials.gov/study/NCT01280344
• [2] Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus — https://clinicaltrials.gov/study/NCT00672074
• [3] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis — https://europepmc.org/article/PMC/PMC13322892
• [4] Evaluation of Research Grade Peptides Marketed Directly to Consumers — https://doi.org/10.20944/preprints202604.1748.v1
• [5] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [6] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
• [7] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
• [9] The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets — https://pubmed.ncbi.nlm.nih.gov/39043357/
• [10] The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus — https://pubmed.ncbi.nlm.nih.gov/38996787/
• [11] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
• [12] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — https://pubmed.ncbi.nlm.nih.gov/42160466/